Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

Anti-CTLA-4 monoclonal antibodies (mAbs) confer a cancer immunotherapeutic effect (CITE) but cause severe immunotherapy-related adverse events (irAE). Targeting CTLA-4 has shown remarkable long-term benefit and thus remains a valuable tool for cancer immunotherapy if the irAE can be brought under co...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xuexiang, Liu, Mingyue, Su, Juanjuan, Zhang, Peng, Tang, Fei, Ye, Peiying, Devenport, Martin, Wang, Xu, Zhang, Yan, Liu, Yang, Zheng, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939041/
https://www.ncbi.nlm.nih.gov/pubmed/29463898
http://dx.doi.org/10.1038/s41422-018-0012-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939041/
https://www.ncbi.nlm.nih.gov/pubmed/29463898
http://dx.doi.org/10.1038/s41422-018-0012-z

Ejemplares similares